MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
13 January 2015 | By Astrazeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses...